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Abstract
Objective: To clarify the presence of oxidative stress in patients with primary angle-closure glaucoma (PACG) and to
investigate the relationship between oxidative stress and PACG.
Methods: Fifty patients with primary angle-closure glaucoma and fifty healthy controls of matched age and gender were
included in the study prospectively. Serum samples were obtained to detect the oxidation degradation products
malondialdehyde (MDA), conjugated diene (CD), 4-hydroxynonenal (4-HNE), advanced oxidation protein products (AOPP),
protein carbonyl (PC), ischemia-modified albumin (IMA) and 8-hydroxydeoxyguanosin (8-OHdG).
Results: The concentration of MDA and CD in PACG patients was significantly higher than those of the control subjects
(P,0.05, P,0.01). The serum 4-HNE concentrations were increased in PACG patients, but the differences with those of the
healthy controls were not statistically significant. Compared to normal subjects, there was significant higher in serum AOPP
and PC in PACG patients (P,0.01). PACG patients had higher levels of 8-OHdG in serum with respect to the comparative
group of normal subjects (P,0.01). When plasma IMA levels in the PACG group were compared with those in the control
group, significant increases in IMA were observed in the former (P,0.05).
Conclusions: Our study demonstrated that IMA is a new biomarker available for assessing oxidative stress in PCAG.
Oxidative stress is an important risk factor in the development of primary angle-closure glaucoma. Increased levels of
oxidative stress products may be associated with primary angle-closure glaucoma.
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Introduction
Glaucoma is a progressive optic neuropathy and is the leading
cause of blindness in the developing and industrialized countries.
Although the initiating causes leading to glaucoma are unknown,
oxidative and nitrative stress appears to play a role in the
progressive neuronal death that is characteristic of glaucomatous
optic nerve damage [1–3]. Increased markers of oxidative stress
that have been reported in glaucoma include protein nitrotyrosine,
carbonyls in proteins, lipid oxidation products and oxidized DNA
bases [4–6]. It is concluded that oxidative stress has a pathogenic
role in glaucoma.
The pathogenesis of glaucoma is multifactorial, and the precise
mechanisms are unclear. Various factors may play an elementary
role in the pathologic course of glaucoma, such as genetic factors,
increased levels of glutamate, changes in nitric oxide metabolism,
and vascular changes [7–9]. One factor, which is increasingly
important in the pathogenesis of glaucoma, is oxidative stress. A
number of studies in vitro and in vivo suggested that oxidative
stress is increased in glaucoma patients. Abu-Amero et al reported
in patients with glaucoma demonstrated the occurrence of
mutations in the mitochondrial genome and a reduced mitochon-
drial respiratory activity in comparison to control subjects [10].
Moreover, it has been ascertained that the antioxidative capacity
in the aqueous humor of patients with glaucoma is markedly
reduced compared to nonglaucomatous eyes [2].
The relationship between oxidative stress and primary open-
angle glaucoma (POAG) has already been reported [2–6,11–13].
Sacca et al reported that a statistically significant correlation was
found among human trabecular meshwork DNA damage, visual
field damage, and intraocular pressure, and concluded that
oxidative stress could induce human trabecular meshwork
degeneration, resulting to an intraocular pressure increase, thus
priming the glaucoma pathogenetic cascade [4]. Feilchenfeld et al
reported that increased nitrotyrosine (a footprint for oxidative
injury) is present in blood vessels and astrocytes in the pre-laminar
optic nerve head in human primary open-angle glaucoma than
controls [5]. However, the relationship of oxidative stress and
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presumed that oxidative stress also play an important role in the
development of primary angle-closure glaucoma.
Taking these studies into account, this study is to evaluate the
oxidative stress parameters in PACG patients and investigate the
relationship between oxidative stress and PACG.
Results
The clinical characteristics of the PACG patients and control
subjects are shown in Table 1. Age and gender of the patient were
not significantly different from those of the control.
As shown in table 2, MDA significantly increased in patients’
serum compared with normal subjects (P,0.01). Conjugated
dienes significantly increased in patients compared to the controls
(P,0.05). The concentration of 4-HNE was a bit higher in PACG
patients, but there was no great difference between the glaucoma
group and the healthy control.
Data presented in Table 3 show that the levels of AOPP, serum
protein carbonyl and serum 8-OHdG significantly increased in
patients compared with the control (P,0.01). And the concentra-
tion of serum IMA greatly increased in patients compared with
normal subjects (P,0.05).
Discussion
Glaucoma is the second leading cause of blindness after cataract
in the world. Glaucoma is a heterogeneous group of eye conditions
with manifestation as early as birth to very late age of onset and
are among most common cause of blindness worldwide. Recent
report estimates that there will be 60.5 million people with primary
glaucoma in 2010 and 79.6 million by 2020 resulting in bilateral
blindness in 8.4 and 11.2 million people by the corresponding
years, respectively [14]. In general, glaucoma is broadly classified
into three major groups: (i)primary open angle glaucoma (POAG);
(ii) primary angle-closure glaucoma (PACG); and (iii) primary
congenital glaucoma [15,16]. Among those subtypes PACG is the
most common form of the glaucoma in China.
The common denominator of these diseases is the involvement of
free radicals. Numerous scientific investigations have confirmed the
presence of oxidative stress in ocular diseases. Indeed, reactive
oxygen species (ROS) may play a significant role for the
pathophysiology in glaucoma [2,4,17]. In ophthalmology, oxidative
stress has been reported to induce and facilitate progression of
cataracts and diabetic retinopathy [18,19]. In glaucoma, antioxi-
dant levels decrease in the aqueous humor in patients with POAG
compared with in the aqueous humor of patients with cataracts,
suggesting that peroxidation may be involved in the development of
glaucoma [2].
Oxidative stress plays a critical role in the development and
progression of glaucoma, but the mechanism is not clear. The
possible sources of increased oxidative stress might include
increased generation of free radicals or impaired anti-oxidant
defence system. In general, oxidative stress, including ROS, can
cause oxidative damage to DNA, proteins, and lipids, leading to
DNA and protein modification and lipid peroxidation, and many
clinical conditions are associated with increased indices of oxidant
stress.
Recent datas indicate that the oxidative stress plays an
important role in the pathogenesis of glaucoma. POAG may be
associated with increased lipid peroxidation and oxidative DNA
damage caused by oxidative stress. Increasing evidences in both
experimental and clinical studies suggests that there is a close link
between oxidative stress and glaucoma [1,2,20]. It had been
considered that oxidative stress contribute to the pathological
processes of glaucoma [6].
Oxidatants are highly reactive compounds with a half-life of
only seconds. It is generally not feasible for in vivo determination.
In contrast, lipids, proteins, carbohydrates and DNA, after being
modified by oxy-radicals, have lifetimes ranging from hours to
weeks, can be measured with biochemical assays, which makes
them ideal markers of oxidative stress. Many biomarkers have
been developed to evaluate oxidative stress. These markers include
lipid peroxidation products (such as acrolein, MDA, conjugated
dienes, F2-isoprostanes and 4-hydroxynonenal), protein oxidation
products (such as AOPP, protein carbonyl) and DNA damage
products (8-OHdG).
The resultant end products, MDA, F2-isoprostanes, CD or 4-
hydroxynonenal (HNE) are well-known markers in the pathologic
molecular process in oxidative stress. In this study, we selected
three biomarkers of lipid peroxidation that are widely used,
sensitive, and appropriate for use in large studies, CD, MDA and
4-HNE. CD is the initial formation of a lipid peroxide. MDA is a
decomposition product of peroxidized polyunsaturated fatty acids.
4-HNE derives from v-6 polyunsaturated fatty acids like linoleic
and arachidonic acid whose conjugated double bonds are an easy
target for species that can extract a hydrogen atom or add to a
double bond [21].
Production of ROS and lipid peroxidation are increased in
glaucoma patients. Babizhayev and Bunin [22] reported increased
levels of lipid peroxides in the aqueous humor, trabecular
meshwork, and Schlemm’s canal in POAG compared with control
eyes, and suggested that lipid peroxidation was responsible for
destruction of the trabecular meshwork and Schlemm’s canal. In
addition, Bunin et al [23] reported that destruction of the drainage
system in POAG is accelerated by lipid peroxidation. Lipid
peroxidation products have been found in significantly higher
concentrations in the aqueous humour and trabecular tissue of
glaucoma patients compared with control subjects [22]. Increased
vitreous and retina MDA levels were also detected in rats with
elevated intraocular pressure (IOP) [24,25]. In our study, we found
that PACG patients had significantly higher MDA and conjugated
dienes compared with control subjects. Therefore, the concentra-
tion of 4-HNE in patients with PACG was elevated in comparison
to control, but the differences with those of the healthy controls
were not statistically significant.
Table 1. Clinical characteristics of PACG patients and health
control.
Health group glaucoma patients
N 50 50
Age (years) 60.9466.95 59.0468.42
Sex (F/M) 25/25 25/25
IOP left eye (mmHg) 16.062.4 27.868.7
*
IOP right eye (mmHg) 15.862.3 24.365.5
*
Cholesterol (mmol/L) 4.9960.65 5.0460.71
Triglycerides (mmol/L) 1.1060.37 1.1860.40
Glucose (mmol/L) 4.5760.72 4.6760.51
Systolic blood pressure(mmHg) 127.265.8 124.968.9
Diastolic blood pressure(mmHg) 79.664.4 78.066.9
Data are means6SD.
*P,0.01 vs healthy subjects.
doi:10.1371/journal.pone.0027218.t001
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chlorinated oxidants, mainly hypochlorous acid and chloramines
(produced by myeloperoxidase in activated neutrophils), has begun
to attract the attention of various investigators [26,27]. AOPP was
described by Witko-Sarsat et al
15for the first time. They are
elevated in patients with renal insufficiency and diabetes mellitus
[28,29]. In our study, we have also determined the level of CD,
AOPP and protein carbonyl, three products protein oxidation,
which were increased, and demonstrated that there were protein
oxidative damage in PACG. Additional, the results show that
AOPP is a biomarker available for assessing oxidative stress in
PCAG, too.
Biomarkers of protein oxidation are often applied when a
battery of markers of oxidative stress status is being studied.
Protein carbonyl formation is a widely utilized marker for protein
oxidation [30]. Protein carbonyl (PC) content is the most general
and well-used biomarker of severe oxidative protein damage. The
measurement of carbonyl groups is considered to be a good
estimation for the extent of oxidative damage to proteins. Serum
protein carbonyl levels revealed a significant increase in glaucoma
patients compare with healthy controls [31]. Protein carbonyl
formation was also identified via proteomic analysis in a chronic
pressure induced rat model of glaucoma [20]. In this study, we
found that the level of protein carbonyl in PACG was increased
significantly. The effect of carbonyl formation on the function of
glutamine synthetase remains to be elucidated but may have
potential consequences on retinal ganglion cell death associated
with glaucoma.
Oxidative deoxyribonucleic acid (DNA) damage can lead to
DNA protein cross linking, strand breaks and base modifications.
Oxidative DNA damage is assessed by measuring levels of 8-
OHdG, an indicator of oxidative DNA damage. It has been
regarded as a novel biomarker of oxidative DNA damage in vivo.
Elevated intraocular pressure due to reduction in aqueous outflow
facility is a major causal effect in glaucoma [32]. The eye’s outflow
system consists of a series of endothelial cell-lined structures in the
angle of the anterior chamber, which also include the trabecular
meshwork. Therefore, the contents of 8-OHdG in serum could be
act as a sensitive biomarker for the glaucoma patients. Levels of 8-
OHdG was determined in human trabecular meshwork (HTM)
specimens collected from patients with primary open-angle
glaucoma (POAG) [4]. The relationship between DNA oxidation,
IOP and visual field (VF) damage and disease duration were also
evaluated. A statistically significant correlation was also found
among oxidative DNA levels, visual field damage and intraocular
pressure. In our study, we found that PACG patients had high 8-
OHdG concentrations. It was concluded that oxidative DNA
damage may induce human trabecular meshwork degeneration,
leading to increase IOP.
Ischemia-modified albumin is a new biochemical marker. It has
been recently reported that IMA is a highly sensitive biomarker,
reflecting the myocardial ischemic condition prior to progression
to myocardial necrosis [33–35]. During acute ischemic conditions,
the metal binding capacity of albumin to transition metals such as
copper, nickel, and cobalt is reduced, generating a metabolic
variant of the protein. This change is quantifiable and commonly
known as IMA [36]. IMA has been studied primarily in selected
populations thought to display myocardial involvement only in the
absence of confounding clinical conditions. However, other organs
seem to be responsible for the increase in IMA. High IMA
concentrations do not seem to depend purely on myocardial
involvement. IMA may not be specific for cardiac ischemia. There
are several data on IMA in patients with different states with
ischemia of non-cardiac origin such as systemic sclerosis,
peripheral vascular disease, skeletal muscle ischemia and diabetes
mellitus [37–39]. But no one concerns PACG.
Ischemia plays a role in the pathogenesis of several diseases
[40,41]. It is believed that ischemia-induced injury plays an
important role in some retinal diseases such as glaucoma,
including open angle glaucoma, closed angle glaucoma, and
normal-tension glaucoma, and central retinal vessel occlusions.
IMA, a metabolic variant of albumin, emerges in ischemic states.
There is as yet no definitive conclusion as to how IMA emerges.
Elevated IMA levels may result from increased oxidative stress,
caused by ischemia reperfusion injury or other mechanisms linked
to primary reduction of coronary blood flow or muscle damage
[42,43]. Some evidence suggest that IMA levels increase in various
acute ischemic conditions, such as myocardial ischemia, skeletal
ischemia, cerebral ischemia, mesenteric ischemia, and pulmonary
ischemia [44,45]. But there is no study in the literature evaluating
Table 2. Serum levels of MDA, conjugated dienes and 4-HNE.
Group MDA (nmol/ml) conjugated dienes (ABSU) 4-HNE(nmol/ml)
Health control 3.5160.84 0.35060.107 14.1662.98
Glaucoma patients 4.3560.81
** 0.40460.102
* 15.2563.28
Data are means6SD.,
*P,0.05,
**P,0.01 vs healthy subjects.
doi:10.1371/journal.pone.0027218.t002
Table 3. Serum levels of AOPP, protein carbonyl and 8-OHdG.
Group AOPP (mmol/L) Protein carbonyl (nmol/ml) 8-OhdG (nmol/ml) IMA (ABSU)
Health control 15.9663.51 2.9460.72 22.4464.95 0.40960.036
Glaucoma patients 17.8863.42
** 3.4260.76
** 25.1865.33
** 0.42360.030
*
Data are means6SD.,
*P,0.05,
**P,0.01 vs healthy subjects.
doi:10.1371/journal.pone.0027218.t003
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that IMA levels were higher in PACG patients compared with that
in the healthy control subjects. This is the first time to our
knowledge in the literature that the correlation between PACG
and serum IMA levels has been compared using a healthy control
group. Moreover, our study demonstrated that IMA is a new
biomarker available for assessing oxidative stress in PCAG.
In conclusion, we found that there were severe lipid peroxida-
tion, oxidative DNA damage and protein damage in the patients
with PACG. These findings suggested the possibility that increased
oxidative stress may be associated with in PACG. Therefore,
assessment of oxidative stress in PCAG patients may be important
for the therapy and prevention of glaucoma.
Materials and Methods
Subjects
The studied group consisted of 50 patients with PACG, who
were recruited from the First Affiliated Hospital of the Harbin
Medical University and the Eye Hospital of Heilongjiang
Province. All subjects underwent a complete ophthalmic exami-
nation including best corrected visual acuity measurements, slit-
lamp biomicroscopy, Goldmann applanation tonometry, gonios-
copy, fundoscopy. The diagnostic criteria for PACG were as
follows: open and non-occludable anterior chamber angles with
gonioscopy (Volk 3 Mirror Gonio Lens, Mentor, USA), glau-
comatous optic disc cupping was identified as a vertical cup-to-disc
ratio of optic nerve head 0.6 or more, difference of the vertical
cup-to-disc ratio 0.2 or more between both eyes, rim width at
superior portion (11–1 h) or inferior portion (5–7 h) of 0.2 or less
of disc diameter or the presence of nerve fiber layer defect. The
exclusion criteria of this study were as follows. Subjects with other
ophthalmic conditions such as primary open-angle glaucoma,
pigment dispersion glaucoma, exfoliative glaucoma, trauma, any
other type of secondary glaucoma were excluded. Subjects who
took vitamins, steroids, or medications were excluded. Active
smokers and subjects with smoking were also excluded. Subjects
who had systemic diseases such as diabetes mellitus or hyperten-
sion were excluded.
Fifty healthy, age-matched subjects were also included for the
control. The control subjects were recruited from subjects who
came to the same hospital for an annual refractive check-up. The
control subjects did not have any history of ocular diseases, and
underwent the same examinations as the patients by the same
investigator. None of the control subjects was taking any
medication. Active smokers and subjects who had smoked were
also excluded. All subjects gave written informed consent to
participate in this study.
Blood sampling
Venous blood samples were collected after 12 h overnight
fasting from each subject. The samples were placed on ice and
centrifuged with an hour at 3500 rpm, 4uC for 15 minutes, and
the supernatants were stored at 220uC and determination of the
samples occurred within 3 months.
Laboratory Analysis
Malondialdehyde assay. Malondialdehyde (MDA) was mea-
sured as thiobarbituric acid-reacting substance (TBARS) pro-
duction in the following manner. 0.1 ml of sample was added to a
1:1:1 (vol/vol/vol) solution of trichloroacetic acid (15%, wt/vol),
thiobarbituric acid (0.375%, wt/vol), and hydrochloric acid
(0.25 M). The mixture was heated at 100uC for 30 min. The
mixture was immediately cooled and then centrifuged (3,500 g for
5 min) to remove undissolved materials. Then the absorbance at
532 nm was determined. The amount of TBARS was calculated
from comparison with authentic malondialdehyde.
Conjugated dienes assay. Conjugated diene (CD) deter-
mined according to the method of Ward et al [46]. Conjugated
dienes extracted from plasma using a 2:1 (vol/vol) mixture of
chloroform and methanol. 4 ml of the chloroform-methanol
mixture, preheated to 45uC, were added to 0.1 ml of serum.
The mixture was then vigorously mixed (with a vortex machine)
for 2 min, then mixed with 2.0 ml of distilled water acidified with
0.1 M HCl to a pH of 2.5. After agitation that used a vortex
instrument, the material was subjected to centrifugation (2,000 g
for 5 min), and 1.5 ml of the lower layer was aspirated, transferred
to a test tube, and dried under a flow of nitrogen gas. The residue
was reconstituted with 1.0 ml of heptane and measured
spectrophotometrically at 233 nm. The results were reported as
absorbance units (ABSU).
Advanced oxidation protein products assay. Advanced
oxidation protein products (AOPP) were quantified as described of
Witko-Sarsat V [47]. We placed 200 ml of serum diluted 1:5 in
phosphate-buffered saline into each well of a 96-well microtitre
plate and added 20 ml of acetic acid to each well. For the
standards, we added 10 ml of 1.16 M potassium iodide (Sigma, St
Louis, MO, USA) to 200 ml of chloramine-T solution (0 to
100 mmol/L) (Sigma, St Louis, MO, USA) in a well and then
added 20 ml of acetic acid. The absorbance of the reaction mixture
was immediately read at 340 nm against a blank consisting of
200 ml of phosphate-buffered saline, 10 ml of 1.16 M potassium
iodide, and 20 ml of acetic acid. AOPP concentrations are
expressed as mmol/L of chloramine-T equivalents.
Protein carbonyl assay. Protein carbonyl concentrations in
plasma were measured by the spectrophotometric assay described
by Reznick and Packer [48]. Briefly, to 200 ml plasma, 4 ml of
10 mmol 2, 4-dinitrophenylhydrazine (DNPH) in 2 mol/L HCl
was added. In another tube, 4 ml of 2 mol/L HCl was added to
200 ml plasma (of the same patient). The tubes were left in the dark
for 1 h at room temperature and were mixed by vortex every
15 min. Five milliliters of 20% trichloroacetic acid solution was
then added to both tubes for a 10 min incubation on ice, after
which the tubes were centrifuged (30006 g, 5 min, 4uC). The
supernatant fluid was discarded and another wash was performed
by using 4 ml 10% trichloroacetic acid. The protein pellets were
broken mechanically and washed 3 times with ethanol–ethyl
acetate to remove free DNPH and lipid contaminants. The final
precipitates were dissolved in 2 ml of 6 mol guanidine
hydrochloride/L, and insoluble materials were removed by
additional centrifugation (30006g, 5 min, 4uC). The absorbance
at l=370 nm was measured spectrophotometrically. The
carbonyl content (nmol/ml) was calculated using eM=22,000.
Ischemia-modified albumin assay. Reduced cobalt-toal-
bumin binding capacity [Ischemia-modified albumin (IMA) level]
was analyzed using the rapid and colorimetric method described
by Bar-Or et al [49]. Two hundred microliters of patient serum
was placed into glass tubes and 50 ml of 0.1% cobalt chloride
(CoCl2N6H2O; Sigma, Sigma-Aldrich Corporation, St. Louis, MO)
in H2O was added. After gentle shaking, the solution was left for
10 minutes to ensure sufficient cobalt–albumin binding. Fifty
microliters of dithiothreitol (DTT) (1.5 mg/ml H2O; Sigma) was
added as a colorizing agent, and the reaction was quenched
2 minutes later by adding 1.0 ml of 0.9% NaCl. Specimen
absorbencies were analyzed at 470 nm using a spectrophotometer.
IMA was calculated from the difference between samples
measured with and without dithiothreitol. The results were
reported as absorbance units (ABSU).
Oxidative Stress in Glaucoma Patients
PLoS ONE | www.plosone.org 4 November 2011 | Volume 6 | Issue 11 | e27218Measurement of 8-hydroxydeoxyguanosin and 4-hydro-
xynonenal. Serum 8-hydroxy-29-deoxyguanosine (8-OHdG)
was measured with enzyme-linked immunosorbent assay
(ELISA) method following the maker’s instructions (Highly
Sensitive 8-OHdG Check, Japan Institute for the Control of
Aging, Fukuroi, Shizuoka). 4-hydroxynonenal(4-HNE) was
measured with enzyme-linked immunosorbent assay (ELISA)
method.
The assay variances of all methods described above were
,10%.
Other biochemical parameters
Blood glucose, triglycerides and cholesterol were determined
using routine clinical chemical assays.
Statistical analysis
Data are presented as mean6SD. All experimental data in this
study were statistically analyzed with SAS 9.13. The statistical
significance was evaluated using unpaired Student’s t-test. Results
were considered significant at P,0.05.
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